Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/134051
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: The effect of low-dose aspirin on frailty phenotype and frailty index in community-dwelling older adults in the ASPirin in Reducing Events in the Elderly study
Author: Espinoza, S.E.
Woods, R.L.
Ekram, A.R.M.S.
Ernst, M.E.
Polekhina, G.
Wolfe, R.
Shah, R.C.
Ward, S.A.
Storey, E.
Nelson, M.R.
Reid, C.M.
Lockery, J.E.
Orchard, S.G.
Trevaks, R.
Fitzgerald, S.M.
Stocks, N.P.
Chan, A.
McNeil, J.J.
Murray, A.M.
Newman, A.B.
et al.
Citation: Journal of Gerontology Series A: Biological Sciences and Medical Sciences, 2022; 77(10):2007-2014
Publisher: Oxford University Press
Issue Date: 2022
ISSN: 1079-5006
1758-535X
Statement of
Responsibility: 
Sara E Espinoza, Robyn L Woods, A R M Saifuddin Ekram, Michael E Ernst, Galina Polekhina, Rory Wolfe ... et al.
Abstract: BACKGROUND: Frailty is associated with chronic inflammation, which may be modified by aspirin. The purpose of this study was to determine whether low dose aspirin reduces incident frailty in healthy older adult participants of the ASPirin in Reducing Events in the Elderly (ASPREE) trial. METHODS: In the U.S and Australia, 19,114 community-dwelling individuals aged ≥70 years (U.S minorities ≥65 years) and free of overt cardiovascular disease, persistent physical disability, and dementia, were enrolled in ASPREE, a double-blind, placebo-controlled trial of 100mg daily aspirin versus placebo. Frailty, a pre-specified study endpoint, was defined according to a modified Fried frailty definition (Fried frailty) and the frailty index based on the deficit accumulation model (frailty index). Competing risk Cox proportional hazards models were used to compare time to incident frailty by aspirin versus placebo. Sensitivity analysis was conducted to include frailty data with and without imputation of missing data. RESULTS: Over a median 4.7 years, 2252 participants developed incident Fried frailty, and 4451 had incident frailty according to the frailty index. Compared with placebo, aspirin treatment did not alter the risk of incident frailty (Fried frailty HR: 1.04, 95% CI 0.96-1.13; frailty index HR: 1.03, 95% CI 0.97-1.09). The proportion of individuals classified as frail, and the trajectory in continuous frailty scores over time, were not different between the aspirin and placebo treatment groups. The results were consistent across a series of subgroups. CONCLUSIONS: Low dose aspirin use in healthy older adults when initiated in older ages does not reduce risk of incident frailty or the trajectory of frailty.
Keywords: aspirin
clinical trials
frailty
inflammation
Description: Advance Access publication November 10, 2021
Rights: © Published by Oxford University Press on behalf of The Gerontological Society of America 2021. This work is written by (a) US Government employee(s) and is in the public domain in the US.
DOI: 10.1093/gerona/glab340
Grant ID: http://purl.org/au-research/grants/nhmrc/334047
http://purl.org/au-research/grants/nhmrc/1127060
http://purl.org/au-research/grants/nhmrc/1135727
Appears in Collections:General Practice publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.